Thank to business We closed, difficulty] for be market for call. you, update [technical XXXX hope you the safe and update Good morning, XXXX. the the Lisa. everyone. to we quarter continue issued well. welcome second business results of after to We'd financial quarter our a and like press earnings Yesterday second with you release
quarterly here Alcorn. XX-Q. in our also on Medical me With the We Harry our and Officer, Scott our Dr. and Chief Kellen; documents found website Media Investors report our section of Chief Financial today can diamedica.com. be Officer filed Form is at Both
First, closed let past with me on this Monday. offering, which few our comments public begin we a
included option you over a exercise as in full of $X book-running the Securities public Guggenheim with Craig-Hallum the share. by that raised National the manager offering the per the a of allotment $XX as sure was which the of offering I'm joint As million, and saw manager manager underwriters book-running lead Holdings at lead price proceeds gross
to first we'll to the we biotech additional to with II stroke not that study adequate We've Over clear of the of offering were represent our share and funds. whose recently opportunity our study. our number we've summer, few believe sold been we we CKD institutional results we this a recognized to we offering offering. we from that two to get have funds, our opportunity have seek the be could this in We months, however, with names Well, with the going investor space to for our a independent bring REDUX of if shareholders conduct also the wait validation reason capital The were and I'm presented primarily last CKD story wish and be DMXXX. continued that to the their to our an until what's plans given cohorts We biotech Phase capital that you from report been funds, investment in had good the would an an was pleased clear, investors, with plan new specialist to share confident deviate this that's I Over an driving have have that ReMEDy in would that data. biotech investors. of will our investors. with to new positions. results past
a to continue it intend the In of from next our also of the this investors product to new number our a in DMXXX, use net study to for offering seeing cohort disease gratifying the also clinical of study participate addition to stroke. existing diabetic offering. and our the initiation very investors, in development our addition to ischemic activities our We proceeds was acute including of subjects kidney and REDUX third
and expand use purposes. working team our and additional general We support other will further to for work to capital the this net proceeds corporate
X, We an of CK in secondary albumin moderate study trial clinical to in our In mLs participants in of our three dosing dosing dose X, to on endpoints. my chronic caused The with for creatinine X and estimated and was pharmacodynamics at the X.X well This begin Dose short-term being or trial patients that study the The what results tolerability me improvements evaluation or diabetes. I of performed glomerular per dose, subcutaneous the in pharmacokinetics normal II for XXXX, favorable moderate in with of overall kg plans disease, as to filtration is we up by assess the was of review to July micrograms CKD. DMXXX rate Type ongoing as identified restore a study Xb kidney a X the DMXXX safety, observed updates included severe or Type kg average micrograms the of of clinical clinical completed increase believe a administered progress Let a CKD CKD REDUX in DMXXX. with trial likely results we or our Phase single affirmed KLKX our of or of to pharmacodynamics in CKD rates urinary per ratio range. UACR. patients. eGFR levels
the DMXXX the UACR drug was with UACR greatest in these Excluding improvements levels, average decrease that as after the greatest at administration hormones We believe and subjects oxide XX results improvements and declined. the then subsequently nitric approximately with normal prostaglandins. increase XX%. the timing of were hours related These correlated occurred
Next, XX levels a having placebo, This for DMXXX after levels the a of to days, at endpoints believe levels placebo compared received statistically of X.X benefits. compared improvement average we observed signal for being glucose disease kidney participants. XX.X blood as The less potential diabetic of small, in that in with represents than included millimoles. Well, group who maintained also albinuria, glucose of millimoles. as the received the were trend We reducing who improvement sustained difference the was product off with and and risk by XX. those above significant kidney the We which with DMXXX sample decrease by which by were completed profile in in as both recurrent blood in while eGFR a day function with mLs comprised DMXXX participants placebo. size normal specifically mean demonstrated experience eGFR improvement a DMXXX reduction subject to restoring healthy to of which to do XX KLKX X was in XX diabetic determined include levels received and kidney of X subset range. the DMXXX a diabetic retinopathy, in with post the with a stroke an function, kidney trial, was disease of glucose impaired measured a function could kidney so along XX treated individuals participants, of patients elevated eGFR eGFR also Patients a the strokes. DMXXX believe hoc mean ReMEDy reducing measured by of analysis of far DMXXX can and
and cohorts. total, albinuria. II If at reduce our to CKD now Based these disease. study regulatory the In it few are over see with chronic treatment with equal based new we and participants of kidney could initiate years Medicines in very kidney optimistic II that clinical we a upon our national these lower upon diseases, diabetic based workshop which studies for USFDA enroll diabetic REDUX and are for collaboration Phase greatly on allowed, a we're metrics the CKD will observations, from perspective, REDUX the XX both participants trial a three excited could eGFR conducted new potentially the upon the Phase Agency third European foundation In focused addition, by registration kidney scientific are burden. the last thresholds cohort in
The Nephropathy. first is with cohort IgA participants on focused
hypertensive with not in who are The Americans second African CKD diabetic.
which administered the being X The points be is are will disease. in for third micrograms X diabetic level at kg, and week. approximately added study for cohort overall DMXXX primary eGFR subcutaneously is weeks per treated kidney albinuria. or end dose Participants XX either with per The twice of efficacy
points to CKD. each impact the Secondary are for the potential focused disease positively underlying end causing on evaluating participants DMXXX
this warrant. our on likely this while to provide not completion activity to we seen reported, with enrollment and as or point, recruit if -- at the a affect sites. combat in two they clinical to the staff of been REDUX the a believe was screening additional combination enrollment consider actions enrollment We We we'll XXXX the August in anticipate of We related guidance implemented to of As to concerns few anticipated study. concerns, participants to able the sites increase X, COVID-XX first clinical one-third and enrollment. study added with some that assist adversely the cohorts the to approximately the visiting have experienced to conditions the July to recently as still and an than subject COVID-XX subjects. address at we continue safety of in or slower complete. patient Due And of we're pandemic of sites, reduction activities have visit study study enroll, site has and pandemic, we the suspension enroll patient's due will recently ability XXth poised
for a with While is data efficacy. results comment to study past studies, the observed this upon in consistent REDUX to indicate time evaluate profile us there or date insufficient safety at
third affect And first and The clinical in that we the addition of COVID be diabetic two related once XX cohorts. sites. third current not recruitment disease, the will cohort ease, do leveraging kidney anticipate pressures and the cohort we'll adversely the
of limited also study, be required REDUX related pressures the and for ease. resuming with States the We able progress the remain will study by optimistic REDUX COVID to once recruitment the rapidly with more screening participant design that contact
option DMXXX's This proportion or these data mechanical just with an patient XX in stroke achieving XX-hour or is absolute those or to those This to tPA. stroke full by Turning patients a In and a to symptom following results placebo. in effect full program represents a full Treatment day was saw recovery the be a receive recovery. new to ReMEDy a that mechanical XX% tPA. We participants, the nearly treatment XX participants most care, or or are with intended group included on ischemic one. full DMXXX those thrombectomy, with XX% did that DMXXX, of measured intended When full only on participants which our either therapeutic with limited into also were who at zero which progressed or total the rehab treated XX lined and we to for thrombectomy XX% eligible palliative treated progressed a score nearly patients treated set patients patients were of increase. is XXX% a relative group and in nearly of This approximately NIHSS DMXXX and our to the population of participants not not not of XX. recovery, increase listeners, did to provide the looked The stroke focuses showed group, and XX% that of DMXXX. the who positive of placebo management. a for treatment respond our acute window for closely to
XX% just to addition, the a In group in in from decreased the subject subject XX% in decrease deaths. absolute DMXXX deaths group, placebo XX%
Compared window patients in efficacy are recoveries therapeutic demonstrated China full upon based results of I also upon with for to that X a extracted improvement half has that first results. note based ischemic were DMXXX interesting a estimates, our or of form a note urine DMXXX tPA over human care, KLKX current to stroke. a would upon small initial approval. at of relatively window treated full these of million similar first XX-hour dosing. While stroke nearly our hours approved to from the as human Based of acute on is kallikrein number which kallikrein, subjects, treatment based was XX% it the an standard approximately an in results
program, stroke Phase Looking the currently for our in III a forward are a of with of proposed stroke. DMXXX treatment study we protocol developing
part from endpoints, our an of clinical evaluation along product firm have provide profile target proposed we feedback engaged payers global to consulting of process, and this neurologists. independent As with a and
are We to that product economic to addressing ensure points of also DMXXX. and deployment reimbursement necessary end want we support the
currently USFDA. would Scott B us this FDA ask to are this would shortly, now to the meeting This XXXX meeting expected agrees, QX take is to fall. the and a a Type request request We likely if like I the meeting through finalizing financials. be with submitted for Kellen place meeting take
